Page 58 - TD-3-4

Tumor Discovery PPAR agonist and cancer

agonist of PPAR-γ, reverses doxorubicin-resistance in an doi: 10.1007/s10637-013-0056-3
osteosarcoma patient-derived orthotopic xenograft model 99. Hau P, Kunz-Schughart L, Bogdahn U, et al. Low-dose
by downregulating P-glycoprotein expression. Biomed chemotherapy in combination with COX-2 inhibitors and
Pharmacother. 2019;118:109356.
PPAR-gamma agonists in recurrent high-grade gliomas-a
doi: 10.1016/j.biopha.2019.109356 phase II study. Oncology. 2008;73(1-2):21-25.
90. To KKW, Tomlinson B. Targeting the ABCG2-overexpressing doi: 10.1159/000120028
multidrug resistant (MDR) cancer cells by PPAR-γ agonists. 100. Vogt T, Hafner C, Bross K, et al. Antiangiogenetic therapy
Br J Pharmacol. 2013;170(5):1137-1151.
with pioglitazone, rofecoxib, and metronomic trofosfamide
doi: 10.1111/bph.12367 in patients with advanced malignant vascular tumors.
Cancer. 2003;98(10):2251-2256.
91. Zhang H, Jing X, Wu X, et al. Suppression of multidrug
resistance by rosiglitazone treatment in human ovarian doi: 10.1002/cncr.11775
cancer cells through downregulation of FZD1 and MDR1 101. Reichle A, Bross K, Vogt T, et al. Pioglitazone and rofecoxib
genes. Anticancer Drugs. 2015;26(7):706-715.
combined with angiostatically scheduled trofosfamide in
doi: 10.1097/CAD.0000000000000236 the treatment of far‐advanced melanoma and soft tissue
sarcoma. Cancer. 2004;101(10):2247-2256.
92. Bräutigam K, Biernath-Wüpping J, Bauerschlag DO, et al.
Combined treatment with TRAIL and PPAR-γ ligands doi: 10.1002/cncr.20574
overcomes chemoresistance of ovarian cancer cell lines. 102. Bahrambeigi S, Molaparast M, Sohrabi F, et al. Targeting
J Cancer Res Clin Oncol. 2011;137(5):875-886.
PPAR ligands as possible approaches for metabolic
doi: 10.1007/s00432-010-0952-2 reprogramming of T cells in cancer immunotherapy.
Immunol Lett. 2020;220:32-37.
93. Vallée A, Lecarpentier Y, Vallée JN. Targeting the canonical
WNT/β-catenin pathway in cancer treatment using non- doi: 10.1016/j.imlet.2020.01.006
steroidal anti-inflammatory drugs. Cells. 2019;8(7):726.
103. Odorizzi PM, Pauken KE, Paley MA, Sharpe A, Wherry EJ.
doi: 10.3390/cells8070726 Genetic absence of PD-1 promotes accumulation of
terminally differentiated exhausted CD8+ T cells. J Exp Med.
94. Chen L, Bush CR, Necela BM, et al. RS5444, a novel PPARγ
agonist, regulates aspects of the differentiated phenotype 2015;212(7):1125.
in nontransformed intestinal epithelial cells. Mol Cell doi: 10.1084/jem.20142237
Endocrinol. 2006;251:17-32.
104. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade
doi: 10.1016/j.mce.2006.02.006 induces responses by inhibiting adaptive immune resistance.
Nature. 2014;515(7528):568-571.
95. Smallridge RC, Copland JA, Brose MS, et al. Efatutazone,
an oral PPAR-γ agonist, in combination with paclitaxel in doi: 10.1016/j.ejca.2023.03.040
anaplastic thyroid cancer: Results of a multicenter phase 1 105. Zhang Y, Kurupati R, Liu L, et al. Enhancing CD8+ T cell
trial. J Clin Endocrinol Metab. 2013;98(6):2392-2400.
fatty acid catabolism within a metabolically challenging
doi: 10.1210/jc.2013-1106 tumor microenvironment increases the efficacy of melanoma
immunotherapy. Cancer Cell. 2017;32(3):377-391.
96. Marlow LA, Reynolds LA, Cleland AS, et al. Reactivation
of suppressed RhoB is a critical step for the inhibition doi: 10.1016/j.ccell.2017.08.004
of anaplastic thyroid cancer growth. Cancer Res. 106. Chowdhury PS, Chamoto K, Kumar A, Honjo T. PPAR-
2009;69(4):1536-1544.
induced fatty acid oxidation in T cells increases the number
doi: 10.1158/0008-5472.CAN-08-3718 of tumor-reactive CD8+ T cells and facilitates anti–PD-1
therapy. Cancer Immunol Res. 2018;6(11):1375-1387.
97. Pishvaian MJ, Marshall JL, Wagner AJ, et al. A phase 1 study
of efatutazone, an oral peroxisome proliferator‐activated doi: 10.1158/2326-6066.CIR-18-0095
receptor gamma agonist, administered to patients with 107. Han J, Alvarez-Breckenridge CA, Wang QE, Yu J. TGF-β
advanced malignancies. Cancer. 2012;118(21):5403-5413.
signaling and its targeting for glioma treatment. Am J Cancer
doi: 10.1002/cncr.27526 Res. 2015;5(3):945.
98. Komatsu Y, Yoshino T, Yamazaki K, et al. Phase 1 study of 108. Coras R, Holsken A, Seufert S, et al. The peroxisome
efatutazone, a novel oral peroxisome proliferator-activated proliferator-activated receptor-γ agonist troglitazone
receptor gamma agonist, in combination with FOLFIRI as inhibits transforming growth factor-β–mediated glioma
second-line therapy in patients with metastatic colorectal cell migration and brain invasion. Mol Cancer Ther.
cancer. Invest New Drugs. 2014;32:473-480. 2007;6(6):1745-1754.

Volume 3 Issue 4 (2024) 15 doi: 10.36922/td.4003